Abstract
The aim of this study was to investigate the frequency and correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats (VNTR) in colorectal cancer (CRC), which can provide valuable information for the design of immunotherapeutic vaccines for this disease. Enzyme-linked immunosorbent assays (ELISA) were used to examine the level of auto-antibodies against survivin and MUC1 VNTR in the serum of 135 CRC patients and 95 healthy volunteers. Using mean absorbance+2 standard deviations (SD) of the healthy samples as a cut-off value, the positive rates of survivin and MUC1 VNTR auto- antibodies in CRC were 31.1% and 18.5%, respectively. Altogether, the survivin and MUC1 VNTR positive samples accounted for 36.3% of the CRC patients, and 7.4% were positive for both. A significant positive correlation was found between levels of specific antibodies against survivin and MUC1 VNTR in the serum of CRC patients (r=0.3652, P<0.0001), suggesting that vaccines against both targets would elicit immune responses more effectively.
Highlights
Colorectal cancer (CRC) is one of the most common malignancies, representing 15% of all diagnosed cancers with an annual incidence of one million new cases worldwide
The auto-antibody levels of survivin and MUC1 variable number tandem repeats (VNTR) were analyzed for correlation and compared between the 135 colorectal cancer (CRC) patients (Figure 5A) and healthy controls (Figure 5B)
This study further explored the correlation of auto-antibodies against survivin and MUC1 VNTR in the serum of CRC patients, which we believe is important for cancer vaccine design
Summary
Colorectal cancer (CRC) is one of the most common malignancies, representing 15% of all diagnosed cancers with an annual incidence of one million new cases worldwide. CRC is the third most common cancer in men, and the second most common cancer in women. The incidence of CRC in China is lower than in Western countries, it has increased in recent years, becoming a substantial burden, in the more developed areas of China (Wan, 2009). Surgery, chemotherapy and radiotherapy are the main treatments of choice for CRC (Penland et al, 2004; Hobday, 2005; Meyerhardt et al, 2005). A more advanced treatment is needed, and increasing attention is being paid to the activation of the patient’s immune system and enhancement of tumorspecific immunity (Speetjens et al, 2011)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
